Abstract
The main treatment for Parkinson's disease is the drug L-3,4-dihydroxyphenylalanine (L-DOPA), which increases the availability of dopamine in the basal ganglia and regulates motor activity. However, the chronic use of L-DOPA can lead to the development of L-DOPA-induced dyskinesias (LIDs). Few treatment options are currently available for managing LIDs. A promising strategy involves the a…